BEST UNLIMITED TURBO LONG CERTIFICATE - ASTRAZENECA | Real-time Borsa Italiana 16:49:51 23/05/2024 BST | ||
| 2.685 EUR | +6.34% |
|
| Current month | +11.97% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 2.685 | +6.34% |
| 22/05/24 | 2.525 | -6.31% |
| 21/05/24 | 2.695 | +18.98% |
| 20/05/24 | 2.265 | -2.37% |
| 17/05/24 | 2.32 | -2.11% |
Real-time Borsa Italiana
Last update May 23, 2024 at 04:49 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| S35330 | |
| ISIN | DE000SW890R1 |
| Date issued | 23/04/2024 |
| Strike | 10,179 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.715 € |
|---|---|
| Lowest since issue | 1.374 € |
| Spread | 0.01 € |
| Spread % | 0.37% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.3
USD
Average target price
169.7
USD
Spread / Average Target
+7.87%
- Stock Market
- Certificates
- S35330 Certificat
